NEW DELHI : Bharat Biotech became the first Indian vaccine manufacturer to have peer-reviewed data for its shots, after results from the company’s phase 1 trial to assess the safety and immunogenicity of Covaxin was published in The Lancet on Thursday.“BBV152 (Covaxin) led to tolerable safety outcomes and enhanced immune responses.
Both Algel-IMDG formulations were selected for phase 2 immunogenicity trials. Further efficacy trials are warranted," the results said.
Algel-IMDG is the adjuvant that Bharat Biotech is using in Covaxin to boost the immune response of the vaccine.Bharat Biotech had submitted data for its phase 1 and 2 studies through a pre-print, which is a non-peer reviewed research result, last month.The data for.